期刊文献+

前列腺癌骨转移灶中BMP-2、BMP-4、BMP-7的表达及临床意义 被引量:5

Expression of BMP-2,BMP-4 and BMP-7 in human metastatic prostate cancer and their clinical significance
暂未订购
导出
摘要 目的检测BMP-2、BMP-4、BMP-7在前列腺癌骨转移灶中的表达,探讨其在前列腺癌成骨性转移中的作用。方法采用免疫组化EnVision法检测28例前列腺癌骨转移病例及17例良性前列腺增生(benign prostate hyperplasia,BPH)病例中BMP-2、BMP-4、BMP-7的表达并对其进行对比分析。结果 BMP-2在所有前列腺癌骨转移灶及BPH病例中均表达,二者中其阳性率及表达强度无明显差异(P>0.05)。BMP-4在前列腺癌骨转移灶及BPH中的阳性率无明显差异(P>0.05),但在前者中BMP-4的表达强度明显高于后者(P<0.05)。BMP-7在前列腺癌骨转移灶中的阳性率及表达强度均明显高于BPH(P<0.05)。在BPH的阳性表达病例中,BMP-2、BMP-4、BMP-7细胞质与细胞核同时阳性的表达率分别为13.3%、7.1%和11.1%,在前列腺癌骨转移灶的阳性表达病例中,BMP-2、BMP-4、BMP-7细胞质与细胞核的同时阳性的表达率均为100%,且细胞核的表达强度明显高于细胞质。结论 BMP-4、BMP-7在前列腺癌骨转移灶中高表达,提示其在前列腺癌的成骨性转移中可能起重要作用。 Purpose To analyze the expression of BMP-2, BMP-4, BMP-7 in prostate cancer with bone metastasis. Methods Immunohistochemical technique was used to detect the expression of BMP-2, BMP-4 and BMP-7 in the bone osteobastic metastastic lesions of prostate cancer and the benign prostate hyperplasia (BPH). Results The expression of BMP-2 was detected in all samples and there was no difference between prostate cancer and BPH. The intensity of positivity of BMP-4 was higher in prostate cancer than that in BPH ( P 〈 0. 05), but the difference of positive rate between these two groups showed no significance. The intensity of positivity and the positive rate of BMP-7 were higher in prostate cancer than that in BPH ( P 〈 0.05 ). The positive rate of staining involving both cytoplasm and nuclear in BMP-2, BMP-4 and BMP-7-positive samples in BPH was respectively 13.3 %, 7.1% and 11.1%, respectively, but these in prostate cancer were all 100%, in which the intensity of nuclear staining was higher than that of cytoplasm. Conclusions The expression of BMP-4 and BMP-7 in the prostate cancer with bone osteobastic metastasis is higher than that in the BPH, which implies that they may play an important role in osteobastic metastasis of prostate cancer.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第8期870-873,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 前列腺肿瘤 骨转移 BMP-2 BMP-4 BMP-7 prostate neoplasms bone metastasis BMP-2 BMP-4 BMP-7
  • 相关文献

参考文献8

  • 1Ibrahim T, Flamini E, Mercatali L, et al. Pathogenesis of osteo- blastic bone metastases from prostate cancer[ J]. Cancer, 2010, 116(6) :1406 -8.
  • 2Weber K L, Bolander M E, Sarkar G. Selective differential finger- printing. A method for identifying differentially expressed genes in a family between two samples[J].Mol Biotechnol, 1998,10( 1 ) : 77 - 81.
  • 3Harris S E, Harris M A, Mahy P, et al. Expression of bone mor- phogenetie protein messenger RNAs by normal rat and human pros- tate and prostate cancer cells [ J ]. Prostate, 1994,24 ( 4 ) : 204 - 11.
  • 4王军起,王强,李望,陈家存,郑骏年,孙晓青,那彦群.骨形态发生蛋白-7在前列腺癌组织中的表达及意义[J].中华泌尿外科杂志,2010,31(7):475-477. 被引量:3
  • 5Feeley B T, Krenek L, Liu N, et al. Overexpression of noggin in- hibits BMP-mediated growth of osteolytic prostate cancer lesions [J]. Bone, 2006,38(2) :154 -6.
  • 6Bobinac D, Maric I, Zoricic S. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer[J]. Croat Med J, 2005,46(3) :389 -96.
  • 7Nishimori H, Ehata S, Suzuki H I, et al. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals [ J ]. J Biol Chem, 2012,287 ( 24 ) : 20037 - 46.
  • 8PoZhao,Ying-ChuanHu,IanC.Talbot.Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma[J].World Journal of Gastroenterology,2003,9(10):2202-2206. 被引量:19

二级参考文献37

  • 1Hidaka C,Goodrich LR,Chen CT,et al.Acceleration of cartitage repair by genetically modified chondrocytes over expressing bone morphogenetic protein-7.Orthop Res,2003,21:573-583.
  • 2Doak SH,Jenkins SA,Hurle RA,et al.Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.Cancer Genet Cytogenet,2007,176:161-165.
  • 3Ye L,Lewis Russell JM,Sanders AJ,et al.HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.Urol Oncol,2008,26:190-197.
  • 4MeGovern M,Voutev R,Maciejowski J,et al.A "latent niche"mechanism for tumor initiation.Proc Natl Acad Sci U S A,2009,106:11617-11622.
  • 5Ishizuka O,Tanahe T,Nakayama T,et al.Prostate specific antigen gleason sun and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.Urology,2005,12:728-732.
  • 6Rao LS, Miller DC, Newcomb EW. Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16^INK4A genes in astrocytomas. Diagn Mol Pathol 1997, 6:115-122.
  • 7Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F,Volkmann M, Wallwiener D, Sinn HP. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998; 78: 1661-1668.
  • 8Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S,Sato K, Hamada K. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999; 59:3783-3789.
  • 9Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J,Bartek J. The P16-cyclinD/Cdk4-PRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-5483.
  • 10Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U,Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M.Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92- 276-284.

共引文献20

同被引文献42

  • 1Oprea-Lager DE, Vincent AD, van Moorselaar RJ, et al. Dual-phase PET-CT to differentiate [1 s F] Fluorom- ethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer[J]. PLOS One, 2012,7 (10) : e48430.
  • 2Ceci F, Castellucci P, Mamede M, et al. (ll)C-Cho- line PET/CT in patients with hormone-resistant pros- tate cancer showing biochemical relapse after radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2013,40(2) : 149-155.
  • 3Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry o{ 18F DCF- BC, a low-molecular-weight inhibitor of prostate-specif ic membrane antigen, in patients with metastatic pros- tate cancer[J]. J Nucl Med, 2012,53(12):1883 -1891.
  • 4Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F- NaF PET/CT for detection of bone metastases in pa- tients with high-risk prostate carcinoma[J]. AJR Am J Roentgenol, 2012,199(5) : 1114-1120.
  • 5Garcia G Jr, Riera E, Vails E, et al. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and llC-choline PET/CT[J]. Clin Nucl Med, 2013,38(2) :120-124.
  • 6Keller JM, Schade GR, Ives K, et al. A novel canine model for prostate cancer[J]. Prostate, 2013,73 (9): 952-959.
  • 7Mocarska A, Staroslawska E, Iwonna ZC, et al. Diag- nostic imaging of the prostate cancer[J]. Pol Merkur Lekarski, 2012,33(198) : 357-363.
  • 8Agarwala S,Shah SB. Ten-year follow-up of avascular nec- rosis of femoral head treated with alendronate for 3 years [ J ]. J Arthroplasty, 2011,26 ( 7 ) : 1128.
  • 9Abd-E1-Barr MM, Cox JB, Antonucci MU, et al. Recombi- nant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population [ J ]. Pediatr Neuro- surg,2011,47(4) :266.
  • 10Weber D, Kotzsch A, Nickel J, et al. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type ⅡB receptor[J]. BMC Struct Bi- ol,2007,7:6.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部